Tags

Type your tag names separated by a space and hit enter

Endocannabinoids and the Cardiovascular System in Health and Disease.
Handb Exp Pharmacol. 2015; 231:393-422.HE

Abstract

The endocannabinoid system is widely distributed throughout the cardiovascular system. Endocannabinoids play a minimal role in the regulation of cardiovascular function in normal conditions, but are altered in most cardiovascular disorders. In shock, endocannabinoids released within blood mediate the associated hypotension through CB(1) activation. In hypertension, there is evidence for changes in the expression of CB(1), and CB(1) antagonism reduces blood pressure in obese hypertensive and diabetic patients. The endocannabinoid system is also upregulated in cardiac pathologies. This is likely to be cardioprotective, via CB(2) and CB(1) (lesser extent). In the vasculature, endocannabinoids cause vasorelaxation through activation of multiple target sites, inhibition of calcium channels, activation of potassium channels, NO production and the release of vasoactive substances. Changes in the expression or function of any of these pathways alter the vascular effect of endocannabinoids. Endocannabinoids have positive (CB(2)) and negative effects (CB(1)) on the progression of atherosclerosis. However, any negative effects of CB(1) may not be consequential, as chronic CB(1) antagonism in large scale human trials was not associated with significant reductions in atheroma. In neurovascular disorders such as stroke, endocannabinoids are upregulated and protective, involving activation of CB(1), CB(2), TRPV1 and PPARα. Although most of this evidence is from preclinical studies, it seems likely that cannabinoid-based therapies could be beneficial in a range of cardiovascular disorders.

Authors+Show Affiliations

Faculty of Medicine and Health Sciences, Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, Royal Derby Hospital Centre, University of Nottingham, Room 4107, Uttoxeter Road, Derby, DE22 3DT, UK. S.Osullivan@nottingham.ac.uk.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26408169

Citation

O'Sullivan, Saoirse Elizabeth. "Endocannabinoids and the Cardiovascular System in Health and Disease." Handbook of Experimental Pharmacology, vol. 231, 2015, pp. 393-422.
O'Sullivan SE. Endocannabinoids and the Cardiovascular System in Health and Disease. Handb Exp Pharmacol. 2015;231:393-422.
O'Sullivan, S. E. (2015). Endocannabinoids and the Cardiovascular System in Health and Disease. Handbook of Experimental Pharmacology, 231, 393-422. https://doi.org/10.1007/978-3-319-20825-1_14
O'Sullivan SE. Endocannabinoids and the Cardiovascular System in Health and Disease. Handb Exp Pharmacol. 2015;231:393-422. PubMed PMID: 26408169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoids and the Cardiovascular System in Health and Disease. A1 - O'Sullivan,Saoirse Elizabeth, PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2015/12/19/medline KW - Artery KW - Atherosclerosis KW - Blood KW - Blood pressure KW - Blood–brain barrier KW - Heart KW - Hypertension KW - Vein SP - 393 EP - 422 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 231 N2 - The endocannabinoid system is widely distributed throughout the cardiovascular system. Endocannabinoids play a minimal role in the regulation of cardiovascular function in normal conditions, but are altered in most cardiovascular disorders. In shock, endocannabinoids released within blood mediate the associated hypotension through CB(1) activation. In hypertension, there is evidence for changes in the expression of CB(1), and CB(1) antagonism reduces blood pressure in obese hypertensive and diabetic patients. The endocannabinoid system is also upregulated in cardiac pathologies. This is likely to be cardioprotective, via CB(2) and CB(1) (lesser extent). In the vasculature, endocannabinoids cause vasorelaxation through activation of multiple target sites, inhibition of calcium channels, activation of potassium channels, NO production and the release of vasoactive substances. Changes in the expression or function of any of these pathways alter the vascular effect of endocannabinoids. Endocannabinoids have positive (CB(2)) and negative effects (CB(1)) on the progression of atherosclerosis. However, any negative effects of CB(1) may not be consequential, as chronic CB(1) antagonism in large scale human trials was not associated with significant reductions in atheroma. In neurovascular disorders such as stroke, endocannabinoids are upregulated and protective, involving activation of CB(1), CB(2), TRPV1 and PPARα. Although most of this evidence is from preclinical studies, it seems likely that cannabinoid-based therapies could be beneficial in a range of cardiovascular disorders. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/26408169/Endocannabinoids_and_the_Cardiovascular_System_in_Health_and_Disease_ L2 - https://dx.doi.org/10.1007/978-3-319-20825-1_14 DB - PRIME DP - Unbound Medicine ER -